- Home
- EVAX vs CANF Comparison
EVAX vs CANF Comparison
Compare EVAX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CANF
- Stock Information
- Founded
- EVAX 2008
- CANF 1994
- Country
- EVAX Denmark
- CANF Israel
- Employees
- EVAX N/A
- CANF N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CANF Health Care
- Exchange
- EVAX Nasdaq
- CANF Nasdaq
- Market Cap
- EVAX 14.3M
- CANF 14.4M
- IPO Year
- EVAX 2021
- CANF N/A
- Fundamental
- Price
- EVAX $1.37
- CANF $1.99
- Analyst Decision
- EVAX Strong Buy
- CANF Strong Buy
- Analyst Count
- EVAX 2
- CANF 2
- Target Price
- EVAX $11.00
- CANF $14.00
- AVG Volume (30 Days)
- EVAX 40.9K
- CANF 65.4K
- Earning Date
- EVAX 10-31-2024
- CANF 11-26-2024
- Dividend Yield
- EVAX N/A
- CANF N/A
- EPS Growth
- EVAX N/A
- CANF N/A
- EPS
- EVAX N/A
- CANF N/A
- Revenue
- EVAX $3,295,000.00
- CANF $667,000.00
- Revenue This Year
- EVAX $4,845.21
- CANF $409.56
- Revenue Next Year
- EVAX $30.30
- CANF N/A
- P/E Ratio
- EVAX N/A
- CANF N/A
- Revenue Growth
- EVAX N/A
- CANF N/A
- 52 Week Low
- EVAX $1.28
- CANF $1.87
- 52 Week High
- EVAX $13.61
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- EVAX 22.79
- CANF 37.14
- Support Level
- EVAX $1.28
- CANF $1.90
- Resistance Level
- EVAX $1.80
- CANF $2.21
- Average True Range (ATR)
- EVAX 0.27
- CANF 0.19
- MACD
- EVAX -0.10
- CANF -0.01
- Stochastic Oscillator
- EVAX 6.08
- CANF 15.00
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).